Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Endocr Pract. 2022 Nov;28(11):1140-1145. doi: 10.1016/j.eprac.2022.08.004. Epub 2022 Aug 7.
The aim of this study was to compare the "time to euthyroidism" and "time spent in euthyroidism" following methimazole (MMI) and radioactive iodine (RAI) treatments.
Three hundred fifty-eight patients with hyperthyroidism, 178 who underwent long-term MMI treatment and 180 patients who underwent RAI treatment, were analyzed. The time to normalization of increased serum values of free thyroxine and triiodothyronine and suppressed serum thyroid-stimulating hormone (TSH) values as well as the percentage of time that the thyroid hormone levels remained within normal ranges during a mean follow-up time of 12 years were compared.
The mean time to euthyroidism was 4.59 ± 2.63 months (range, 2-16 months) in the MMI group and 15.39 ± 12.11 months (range, 2-61 months) in the RAI group (P < .001). During follow-up, the percentage of time spent in euthyroidism was 94.5% ± 7.3% and 82.5% + 11.0% in the MMI and RAI groups, respectively (P < .001). Serum TSH values above and below the normal range were observed in 5.3% and 0.2% of patients, respectively, in the MMI group and 9.8% and 7.7% of patients, respectively, in the RAI group (P < .001). The time to euthyroidism and the percentage of time spent in euthyroidism in 40 RAI-treated patients with euthyroidism were similar to those in the MMI group and significantly shorter than those in the RAI-treated hypothyroid and relapsed subgroups. In patients who continued MMI therapy for >10 years, the percentage of time spent in euthyroidism was >99%.
In our cohort of selected patients, MMI therapy was accompanied by faster achievement of the euthyroid state and more sustained normal serum TSH levels during long-term follow-up compared with RAI therapy.
本研究旨在比较甲巯咪唑(MMI)和放射性碘(RAI)治疗后甲状腺功能亢进患者达到甲状腺功能正常的“时间”和“处于甲状腺功能正常的时间比例”。
分析了 358 例甲状腺功能亢进患者,其中 178 例接受了长期 MMI 治疗,180 例接受了 RAI 治疗。比较了血清游离甲状腺素和三碘甲状腺原氨酸值恢复正常及血清促甲状腺激素(TSH)值被抑制的时间,以及在平均 12 年的随访期间甲状腺激素水平处于正常范围内的时间比例。
MMI 组达到甲状腺功能正常的平均时间为 4.59 ± 2.63 个月(范围,2-16 个月),RAI 组为 15.39 ± 12.11 个月(范围,2-61 个月)(P<.001)。在随访期间,MMI 组和 RAI 组处于甲状腺功能正常状态的时间比例分别为 94.5%±7.3%和 82.5%±11.0%(P<.001)。MMI 组分别有 5.3%和 0.2%的患者血清 TSH 值高于和低于正常范围,RAI 组分别有 9.8%和 7.7%的患者血清 TSH 值高于和低于正常范围(P<.001)。40 例甲状腺功能正常且继续接受 RAI 治疗的患者,其达到甲状腺功能正常的时间和处于甲状腺功能正常状态的时间比例与 MMI 组相似,且明显短于甲状腺功能减退和复发亚组。继续接受 MMI 治疗>10 年的患者,处于甲状腺功能正常状态的时间比例>99%。
在我们选择的患者队列中,与 RAI 治疗相比,MMI 治疗可更快达到甲状腺功能正常状态,并在长期随访期间维持更持久的正常血清 TSH 水平。